(MSD) Welcomes News That Pharmac Is Proposing To Fund KEYTRUDA® (pembrolizumab) For 5 Additional Cancer Types

Merck Sharp & Dohme (New Zealand) Limited (MSD) welcomes news that Pharmac is consulting on a funding proposal for KEYTRUDA® (pembrolizumab) for five additional types of cancer.